At a glance
ClinicalIndex Comparison RecordPhase 2Active· 139 target
Drug / intervention
PLB1004drug
Likely dose
PLB1004 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
In Brief
A Phase 2 clinical trial evaluating PLB1004 for NSCLC (Non-small Cell Lung Cancer). Active but no longer recruiting, targeting 139 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC (Non-small Cell Lung Cancer)
CountriesChina
Collaborators--
Timeline
Phase 2Active
2024202520262027
Enrollment StartJul 2023
First PostedAug 2023
Primary CompletionMar 2025
TodayJul 2026
Study CompletionDec 2026
First PostedAug 29, 2023
Enrollment StartJul 21, 2023
Primary CompletionMar 6, 2025
Study CompletionDec 30, 2026
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 2.8 years ago
Interventions
PLB1004drug
PLB1004 is a capsule in the form of 80mg and 40mg.